Similarity - Novel probiotic Enterococcus faecium IS-27526 supplementation increased total salivary sIgA level and bodyweight of pre-school children: A pilot study by Ingrid Suryanti Surono, M.Sc., Ph.D., Ir.
lable at ScienceDirect
Anaerobe 17 (2011) 496e500Contents lists avaiAnaerobe
journal homepage: www.elsevier .com/locate/anaerobeMolecular Biology, Genetics and Biotechnology
Novel probiotic Enterococcus faecium IS-27526 supplementation increased total
salivary sIgA level and bodyweight of pre-school children: A pilot study
Ingrid S. Surono a,b,*, Fiona P. Koestomo c, Nuni Novitasari c, Fransiska R. Zakaria c,
Yulianasari d, Koesnandar b
a Southeast Asian Ministers of Education Organization (SEAMEO), Regional Center For Food and Nutrition (RECFON), University of Indonesia, 6 Salemba Raya, Jakarta 10430,
Indonesia
bAgency for the Assesment and Application of Technology-Center for Bioindustrial Technology, Puspiptek Raya, Serpong, Tangerang, Indonesia
cDepartment of Food Technology and Human Nutrition, Bogor Agricultural University, Darmaga Campus, Bogor, Indonesia
d Teluk Naga Public Health Center, Tangerang, Banten Province, Indonesiaa r t i c l e i n f o
Article history:
Received 20 December 2010
Accepted 9 June 2011
Available online 5 July 2011
Keywords:
Dadih
Novel probiotic
Salivary sIgA
Enterococcus faecium IS-27526
Weight gain
Pre-school children* Corresponding author. Southeast Asian Minister
(SEAMEO), Tropical Medicine and Public Health (TR
Center for Community Nutrition (RCCN), University o
Jakarta 10430, Indonesia. Tel./fax: þ62 21 31902950.
E-mail address: gridsw@yahoo.com (I.S. Surono).
1075-9964/$ e see front matter  2011 Elsevier Ltd.
doi:10.1016/j.anaerobe.2011.06.003a b s t r a c t
Enterococcus faecium IS-27526 is a novel probiotic isolated from dadih, an Indonesian traditional fer-
mented buffalo milk. A 90 days randomized double-blind placebo-controlled study ofpre-post trial was
conducted in pre-school children with two groups, placebo and probiotic group. Ultra High Temperature
low fat milk was used as a carrier in each group. The aims of this study were to investigate the effect of E.
faecium IS-27526 in milk on humoral immune response and on bodyweight of pre-school children. Total
serum IgA and total salivary sIgA were measured by sandwich ELISA. The bodyweight of young children
was measured. The results showed that total serum IgA did not signiﬁcantly increase in the probiotic
group compared with the placebo group. Total salivary sIgA level and the bodyweight signiﬁcantly
increased (p < 0.05) in probiotic groups compared to the placebo. Changes of total salivary sIgA level
were signiﬁcantly higher in underweight children supplemented with probiotic. Weight gain was
observed signiﬁcantly in children with normal bodyweight supplemented with probiotic. Neither
mortality nor weight loss was recorded throughout the study. Taken together, novel probiotic E. faecium
IS-27526 has signiﬁcant positive effects on humoral immune response, salivary sIgA, in underweight pre-
school children, and on weight gain of pre-school children.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
The human intestinal tract harbors a large, active, and complex
community of microbiota. The intestine is a highly sophisticated
organ contains up to 400-500 different species of bacteria, both
harmful and commensals [1]. This microbiota plays a key role in the
host’s overall health through its metabolic activities and physio-
logical regulation such as promotion of nutrient absorption,
synthesis of bioactive compounds, improvement of intestinal
barrier function, motility, resistance to pathogens or modulation of
the immune system [2]. Alteration of the microbiota may cause
some direct or indirect digestive pathologies like infectious
diseases, chronic inﬂammation [3] and metabolic disorders [4]. As of Education Organization
OPMED) Network, Regional
f Indonesia, 6 Salemba Raya,
All rights reserved.healthy intestinal microbiota is considered to be important for
priming of the infants’ mucosal and systemic immunity.
The intestinal microbiota may be modiﬁed temporarily by
nutritional changes in the diet. In particulary the consumption of
pro- or prebiotics can restore or maintain the intestinal ecosystem
by [5,6].
Probiotic deﬁned as a “live microorganism which when
administered in adequate amounts confers a health beneﬁt on the
host” [7]. Criteria for the selection of probiotics are safety, tolerance
to gastrointestinal conditions, ability to adhere to the gastrointes-
tinal mucosa and competitive exclusion of pathogens [8,9]. Adhe-
sion to the intestinal mucosa would allow colonization, although
transient, in human intestinal tract and has been related to the
ability to modulate the immune system especially during its
development [10].
The established probiotics that meet these criteria are generally
lactic acid bacteria (LAB), most commonly Lactobacillus and Biﬁ-
dobacterium species, but Lactococcus, Streptococcus, and Entero-
coccus species, as well as some nonpathogenic strains of Escherichia
I.S. Surono et al. / Anaerobe 17 (2011) 496e500 497coli, and certain yeast strains also qualify [11]. LAB in foods have
a long history of safe use [12], and dadih is safe for human
consumption for hundreds of years [13].
Dadih is fermented buffalo milk in bamboo tubes by natural
lactic acid bacteria and thought to be beneﬁcial for human health
due to the presence of natural lactic acid bacteria involved in the
fermentation [13]. Our interest in conducting human study on
Enterococcus faecium IS-27526 was based on in vitro tolerance to
acid and bile [14], their antimicrobial activity against pathogenic
bacteria and antimutagenic properties [15] in vitro adhesion and
competitiveness against pathogen [7,16] and safety of this strain in
animal experiments (unpublished data). The present study was
designed to i) investigate the immunomodulatory property of E.
faecium IS-27526 especially on humoral immune response, ii) to
evaluate its effect on bodyweight of pre-school children, and iii) to
assess the safety of novel probiotic E. faecium IS-27526.2. Materials and methods
2.1. Strain, culture condition and probiotic preparation
E. faecium IS-27526 was isolated from dadih fermented milk
[15] and was identiﬁed by 16S rRNA gene sequencing as E. faecium
(GenBank accession no. EF068251). The LAB isolate was cultured
in de Man Rogosa Sharpe (MRS) broth (Oxoid, Basingstoke, UK) for
48 h at 37 C, harvested by centrifugation, lyophilized and stored
in the Functional Foods Forum Culture Collection, University of
Turku, Finland. For assays with freeze dried probiotic, lyophiliza-
tion was prepared at the Center of Biotechnology, Agency for the
Assessment and Application of Technology, Serpong, Banten
Province, Indonesia. The bacteria was cultivated in MRS broth in
a 10 L fermentor for 16 h at 37 C under aerobic conditions, har-
vested by centrifugation (3200  g, 4 C, 20 min), and washed
twice with phosphate-buffered saline (PBS; pH 7.0), frozen
at 80 C, and lyophilized. Purity and viability of the lyophilized
cells were tested on MRS agar plates before and during the study
period.2.2. Subjects and experimental methods
The present pilot study was conducted according to the guide-
lines laid down in the Declaration of Helsinki and all procedures
involving human subjects were approved by the Ethical Committee
of Faculty of Medicine, University of Indonesia. Written informed
consent was obtained from all parents or guardians of the study
children.
2.2.1. Subjects
After informed consent, eighty one apparently healthy pre-
school children (39 boys and 40 girls, between 15 and 54
months age, mean age 33 months) who lived in Teluk Naga sub
District, Tangerang, Banten Province, Indonesia were recruited.
Thorough physical examination was conducted on each partici-
pant, including a complete medical history by a medical doctor,
and anthropometric measurements (bodyweight and height) by 2
trained anthropometrists. Their parents or guardians were inter-
viewed on the morbidity and dietary intake of study children, as
well as the household general socio-demographic data, an inter-
viewer administered using the structured questionnaire was
collected to ﬁnd out information on the health condition, and
nutritional status of each subject according to WHO [17]. Subject
volunteers suffering from inﬂammatory illnesses or who had been
treated with antibiotics in the last two weeks or during study
period were excluded.2.2.2. Design
This pilot study was conducted in a randomized, placebo-
controlled, double-blinded pre-post trial. The trial required oral
consumption of probiotic E. faecium IS-27526 over a total period of
90 days. The 79 subject volunteers met the inclusive criteria were
randomly assigned in consecutive way. Among the placebo group
(n ¼ 40), there were 23 girls and 17 boys, received 1 mg malto-
dextrin in 125 ml commercial UHT low fat milk, and the probiotic
group (n ¼ 39), there were 17 girls and 22 boys administrated with
1 mg lyophilized E. faecium IS-27526 (2.31 108 cfu/day) in 125 ml
commercial UHT low fat milk everyday for a period of 90 days. The
UHT milk was prepared by Ultra Jaya Milk Co. Bandung, West Java,
Indonesia).
The subjects were instructed to abstain from fermented dairy
products during intervention, but otherwise maintained their usual
diet and lifestyle. Antibiotic consumption two weeks prior to
intervention and during experimental days were excluded, and no
vaccination procedure was done during the study period. Compli-
ance of intake were monitored and assured by care givers, village
midwives from Teluk Naga public health center throughout the
study period. Physical examination, morbidity and anthropometric
measurements were recorded four times, pre-intervention and at
months 1, 2 and 3 during the intervention period. Saliva and blood
samples were collected at baseline (control sample) and after 90
days of supplementation (test sample), and kept frozen at 20 C
until being analyzed.
The main parameters studied were total serum IgA and total
salivary IgA levels, while the other parameter was the increment of
children’s bodyweight in probiotic and placebo group by
comparing the pre-treatment and post-treatment values. Adverse
events and adverse effects such as morbidity, mortality and
lowering bodyweight during 90 days supplementation observed to
validate the safety of probiotic.
2.3. Probiotic administration
Subjects were administered probiotic or placebo as follows:
1 mg lyophilized E. faecium IS-27526 or maltodextrin was added
into 125 ml UHT low fat milk in tetra pack packaging, and held for
1 h at room temperature to allow the lyophilized probiotic being
viable prior to administrated to the subjects. Daily supplementation
in both groups was conducted at Teluk Naga public health center
and was given by trained village midwives and care givers with
hygiene precaution.
2.4. Blood and saliva collection
Saliva specimen were collected from the mouth on a single
occasion directly into sterilized tubes. All saliva samples were
centrifuged for 15 min at 10,000  g, 4 C to remove cells and
debris. Blood were withdrawn by professional nurses, before and
after the supplementation. Blood were collected by using dispos-
able wing needle (5 ml). Blood samples were allowed to clot at
room temperature for 3 h. Serumwas collected by centrifugation at
2500 revolutions per minute (rpm) for 20 min at 4 C. Serum and
supernatant of saliva were kept at 20 C until used.
2.5. Anthropometric assessment
Weight and height of the children were recorded. A 2-melong
and 1-mmewide metal tape (Microtoise-Stanley-Mabo Ltd, Poissy,
France) was used for height measurement to the nearest 0.1 cm.
Weight was measured using a digital scale (UNISCALE, Seca).
Children were weighed using indoor light clothing and without
shoes and their weight was recorded to the nearest 0.1 kg.
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Fig. 1. The mean elevated values of total salivary IgA levels (mg/ml) based on their
nutritional status, weight-for-age Z score (WAZ).
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value was used for data entry.
Three anthropometric indices are generally used as proxy
measurements for children’s nutritional status; height-for-age Z-
score (HAZ), weight-for-age Z-score (WAZ) and weight-for-height
Z-score (WHZ) [17]. A cutoff of -2SD was used to distinguish
normal children from those stunted (HAZ <2) or underweight
(WAZ <2) or wasted (WHZ <2). In this study, nutrition status
was assessed using the weight-for-age Z score (WAZ).
2.6. Antibody immunoglobulin A (IgA) quantiﬁcation with enzyme-
linked immunosorbent assay (ELISA)
The serum antibody and salivary IgA titers (IgA levels) were
measured by sandwich ELISA, modiﬁcation of Becton Dickinson’s
ELISA method with horseradish peroxidase. There are four basic
steps involved: 1) coating, 2) incubation the test sample and stan-
dard, 3) adding a horseradish peroxides-labeled antibody and 4)
adding the substrate and indicatordye todetect thepositive reaction.
Mouse monoclonal antibody anti-human IgA (Sigma, USA),
diluted 1:1000 in carbonate buffer were added at 100 ml/well to
coat the 96-wells-Maxisorp microplates ﬂat bottom (Nunc, USA),
incubated at room temperature, overnight. After incubation, the
plates were washed three times with washing solution PBS-Tween
20 (0.05%). Blocking was performed by use of 100 ml phosphate
buffer containing 0.5% bovine serum albumin (BSA) at room
temperature for 2 h 15 min and washed three times. Sera was
diluted 10 times while saliva was diluted 15 times in PBS.
One hundred microliters of sera or 50 mL of saliva samples (in
duplicate) and standard human IgA (Sigma, USA) samples (in
duplicate) each was pipetted into microtitre wells. The plates were
incubated for 2 h at room temperature. The wells were washed
three times with washing solution. Then 100 ml/well of goat anti-
human IgA conjugated with horseradish peroxidase (HRP)
(Sigma, USA), diluted 1:20,000 in PBS were pipetted into each well,
and the plates were incubated at room temperature in the dark for
2 h. The wells were washed three times with washing solution and
tapped dry. A fresh substrate solution tetramethylbenzidine (TMB),
100 ml/well was added, and the plates were incubated for 30 min at
room temperature in the dark. The enzyme reaction was stopped
with 100 ml/wellof1.23 M H2SO4 and the optical density (OD) was
read by Multiscan ELISA reader at 450 nm (Labsystem, Finland).
Samples were analyzed in triplicate. IgA levels were detected by
using a standard curve. Salivary IgA levels were quantitated by
using appropriate dilution of a standard IgA sample with a known
concentration of IgA, provided by the manufacturer (Sigma, USA)
and expressed as mg/ml.
2.7. Statistical analysis
Comparison of the means of IgA level within group was tested
by paired t-test, and to compare the mean changes of IgA level after
90 days supplementation between group, the t test was used. The
data were checked for normality by the KolmogoroveSmirnov test.
The mean weight gain was analysed by Mann-whitney, and the
mean bodyweight by Wilcoxon tests. The P level of 0.05 was
considered as signiﬁcant [18].
3. Results and discussion
Among the placebo group, twenty subjects were underweight,
ten subjects severe underweight and nine subjects were in normal
bodyweight, and in probiotic group, twenty two subjects were
underweight, seven subjects severe underweight and ten subjects
were in normal bodyweight.Total serum IgA level was not signiﬁcantly different after 90 days
supplementation, between probiotic and placebo group, however,
tended to increase in both group. In probiotic group, the total IgA
concentrations elevated by (54 185 mg/ml), from 220  132 mg/ml
to 274  229 mg/ml, higher than in placebo group (35  250 mg/ml),
from 231  124 mg/ml to 267  255 mg/ml. The increase of total
serum IgA level in placebo group might be due to the supplemen-
tation of 125 ml UHT low fat milk for 90 days as probiotic vehicle.
Total salivary sIgA level in placebo group was increased by
400  136 mg/ml, while in probiotic group was increased by
919  162 mg/ml. The results indicate there is a remarkable higher
augmentation of total salivary sIgA level of children in probiotic
group compared to placebo group.
Based on their bodyweight, Fig. 1 demonstrates signiﬁcant
elevation of total salivary sIgA of underweight children in probiotic
group, higher than the placebo group after 90 days E. faecium IS-
27526 (108 cfu/day) supplementation. It is interesting that E. fae-
cium IS-27526 enhances total salivary sIgA level in underweight
children.
The augmentation of humoral immune response by E. faecium
IS-27526 is similar to the adjuvant action previously demonstrated
by previous studies. L. casei at 107 cfu/day improved mucosal
immune system and increased sIgA secreting cell signiﬁcantly in
malnourished mouse [19], in line with the results of current study.
The increase of total salivary sIgA level in placebo group might
be due to milk supplemented as probiotic carrier given to both
groups, placebo and probiotic group. The effect of milk supple-
mentation was signiﬁcant especially because the children were
underweight. However, supplementation of E. faecium IS-27526
with milk signiﬁcantly elevated the changes of salivary sIgA level
in underweight children than milk only as shown in Fig. 1.
The ﬁrst contact between ingested bacteria and the immune
system of the host is in the gut-associated lymphoid tissue (GALT).
The human intestine is the largest mass of lymphoid tissue in the
body. Different components of the mucosal immune system act to
focus a speciﬁc response against exogenous antigens. sIgA together
with the innate mucosal defenses provide the ﬁrst line of defense
against microbial antigens at the intestinal mucosal surface [20].
sIgA inhibits the colonization of pathogenic bacteria in the gut, as
well as the mucosal penetration of pathogenic antigens [21]. The
ability of probiotics to modulate IgA concentrations in the gut has
been the subject of several studies. The results obtained in the
present study showed that the increment of sIgA levels were
Fig. 2. Linear regression of bodyweight in both groups. Y1 represents placebo group,
and y2 represents probiotic group.
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than placebo group.
E. faecium IS-27526 has been shown to adhere to human
intestinal mucus and has ability to inhibit adhesion, displace
previously adhered pathogens, and compete for adhesion sites in
intestinal human mucus [16]. E. faecium IS-27526 appeared to have
good autoaggregation abilities [7]. Adhesion to intestinal mucosa
has been reported for most of the current probiotic strains with
demonstrated clinical efﬁcacy. Adhesion may allow colonization by
the speciﬁc strain in human gastrointestinal tract. Colonization
promotes the production of sIgA. The most likely explanation for
the enhancement of the sIgA response is the adhesion as well as
colonization properties of E. faecium IS-27526. Bacterial aggrega-
tion could be the factor in promoting the gut colonization of
beneﬁcial microorganisms [22,23].
Salivary IgA (sIgA) are produced mainly by the Mucosa Associ-
ated Lymphoid Tissue (MALT) and better reﬂect intestinal immune
response than monomeric IgA (serum IgA). The best sample for
assessment of sIgA is obtained from gut lavage ﬂuid or saliva.
Although saliva may not be the optimal source to reﬂect the
mucosal immune response, saliva was easy to obtain from human
and reﬂective of MALT activity [24].
In order to inﬂuence the immune system, a probiotic must
activate the lymphoid cell in the MALT. It has also been reported0
0.5
1
1.5
2
2.5
3
3.5
severe underweight unde
Nutritional
w
e
ig
h
t
g
a
in
(
k
g
)
placebo
probiotic
Fig. 3. Weight gain based on nutritional sthat cell wall peptidoglycan is known for a long time to have an
adjuvant activity. These structures have been found to be involved
in the adhesion of LAB to the intestinal mucosal surface [25].
There are concerns about the use of enterococci for human
probiotic purposes. However, in our in vivo study, there was no
adverse effect recorded inWistar rats administratedwith E. faecium
IS-27256 (data not shown) and this study also reveals that there
was no adverse effect in supplementing E. faecium IS-27256 to
immunocompromised subjects, underweight children, as shown by
no lowering bodyweight, and neither gastroenteritis morbidity nor
mortalilty was observed. Hence, safety of novel probiotic E. faecium
IS-27256 has been validated.
The dominant microorganism in human intestine may play
a role in inhibiting the growth of pathogens [26,27]. Some speciﬁc
components of microbiota also have been associated with beneﬁ-
cial effects of the host, such as promotion of gut maturation and
integrity, antagonisms against pathogens and immune modulation
[28]. Their absence or low viability may cause varying degrees of
digestive problems.
Probiotics have been designed to modify the balance of the
existing ﬂora by directly providing high quantities of microbes
belonging to species that are normal inhabitants of the intestinal
microﬂora [29]. Probiotics and their metabolite activity have been
found to have beneﬁcial health effect such as, stabilization the
intestinal microbiota, antagonisms against pathogens, and increase
immune response that may lead to increase the general health.
The ability of this probiotic strain in inhibiting pathogens may
maintain the integrity of epithelial cell of the intestine so that the
nutrient absorption might be optimum in normal bodyweight
children, as a consequence, the weight gain in normal bodyweight
children supplemented with E. faecium IS-27526 for 90 days
signiﬁcantly higher than the placebo group. Bodyweight is a good
parameter to know the general health condition of the host in short
time periods of intervention.
The mean bodyweight gain in probiotic group was
1.28  0.94 kg, from 10.13  1.22 kgto 11.41  1.31 kg, while in
placebo group was 0.99  0.99 kg from 10.01  1.58 kg to
11.0  1.87 kg.
Fig. 2 shows the linear regression for placebo group,
y ¼ 0.0714x þ 10.054, R2 ¼ 0.8466 while in probiotic group,
y¼0.1071xþ 10.018,R2¼ 0.9595. Yaxis represents bodyweight (kg)
andx axis represents supplementation time (week). The slope or
regression coeﬁcient at probiotic group is (0.107), bigger than
placebo group (0.0714), means that in every one week supple-
mentation the bodyweight of children in probiotic group may
increase by 0.107 kg, while the bodyweight of children in placeborweight normal bodyweight
status (WAZ)
tatus, weight-for-age Z score (WAZ).
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27526 at 108 cfu/day and 125 ml low fat milk for 90 days may
increase the bodyweight of children by 1.5 times higher than
supplementation of 125 ml low fat milk only.
Based on the nutritional status of subjects, weight gain was
found to be signiﬁcant in children with normal bodyweight sup-
plemented with probiotic (Fig. 3), andmight be due to the adhesion
and colonization of E. faecium IS-27256, which may maintain the
integrity of intestine, so that facilitating optimum nutrient
absorption. Hence, the health promoting effects might be related to
the biological activity of probiotic bacteria. A relation between
in vitro adhesion and in vivo colonization has been reported [12]. In
addition, adhesion to and colonization of the mucosal surfaces are
possible protective mechanisms against pathogens through
competition for binding sites and nutrients or immune modulation
[13]. The same strain was also previously studied for its in vitro and
in vivo probiotic attributes such as resistance to acidity, bile toler-
ance, surface hydrophobicity, aggregation adhesion properties, and
competitiveness against pathogens [14,7,16], and this human study
conﬁrmed the probiotic function of E. faecium IS-27256 in human.
4. Conclusion
Taken together, E. faecium IS-27526 together with milk was
signiﬁcant in augmenting the salivary sIgA level in underweight
children, and gaining weight of children with normal bodyweight.
Moreover, safety has been validated in vulnerable population such
as underweight young children. Hence, E. faecium IS-27526 hold
great promise as potential novel probiotic strain in stimulating the
total salivary sIgA level better than milk only in underweight pre-
school children. The increase of secretory IgA level is important
to protect the mucosal surface from infectious diseases.
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